Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by Nico Popp on May 17th, 2022 | 09:54 CEST

Alzheimer's share? Ask the CEO! Valneva, NervGen Pharma, Bayer

  • Biotech
  • Pharma

High blood pressure, diabetes, stroke and Alzheimer's disease are scourges of our time. As people in industrialized countries grow older, it becomes increasingly likely that they will also suffer from one of these diseases. While there is likely to be a genetic predisposition for all of the ailments mentioned, lifestyle also plays a role. Lack of exercise and obesity often leads first to high blood pressure, then to diabetes, and ultimately to even worse conditions. In the event of a pandemic, all people with such pre-existing conditions belong to a high-risk group. Reason enough to take a closer look at stocks related to these issues and ask how investors can profit.

Read

Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

  • Biotechnology

No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...

Read

Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

  • Biotechnology
  • Pharma
  • Investments

Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

Read

Commented by Juliane Zielonka on April 21st, 2022 | 13:58 CEST

Bayer AG, Perimeter Medical, Twitter - Shareholder interests drive share price performance

  • medtech
  • Technology

The life science and medical technology sectors offer investment opportunities. Whether with old hands like Bayer AG or up-and-coming innovative startups like Perimeter Medical, each company has its own fascination. Strong corporate management that acts in the interests of shareholders provides additional confidence. The latter, in particular, is currently being put to the test at the short messaging service Twitter. Elon Musk's takeover bid threatens to dilute existing investors' shares with a poison pill.

Read

Commented by Nico Popp on April 20th, 2022 | 12:04 CEST

Where the music is playing now: BioNTech, MAS Gold, Bayer

  • Gold
  • Biotech

Capitalism is the best system when it comes to distributing goods effectively. Supply and demand first make scarce goods expensive and then turn them into a promising business area. That is what happened with vaccines. Today, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is warning of an oversupply of Corona vaccines - two years ago, things looked very different. While biotech stocks such as BioNTech are being penalized, it is important to identify tomorrow's opportunities. Scarcity plays an important role here.

Read

Commented by Stefan Feulner on April 19th, 2022 | 12:10 CEST

Bayer, Defence Therapeutics, Formycon - Biotech stocks facing transformation

  • Biotechnology

The pharmaceutical industry proved to be a key industry in the Corona pandemic, developing tests, vaccines and drugs at record speed and making them available in large quantities. In the process, biotechnology emerged as the innovative engine. The development of new compounds is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs will expire in the future or has already expired. For this reason, the pharmaceutical industry is now entering biotechs much more frequently in the early development phases of a new drug. As a result, early-stage development companies already offer opportunities for multiplication.

Read

Commented by Juliane Zielonka on April 15th, 2022 | 12:01 CEST

mm2 Asia, Nvidia, Bayer AG - Digital marketplaces with high scalability

  • entertainment
  • Digitization
  • nft

Shanghai is currently experiencing the totalitarian proportions of a zero-COVID strategy. Due to soaring cases, 26 million people have to go into a harsh lockdown. After more than two years of the pandemic, the images from the Chinese metropolis seem all the more disturbing. Helplessness is spreading. People are tired of the inhumane measures. Those who test positive have to spend their quarantine in specially equipped hospitals, separated from their families and other foreign positives. The dystopian experiences of the Corona Pandemic, which everyone has personally experienced in recent months, provide an unexpectedly timely stage for arguably the most spectacular re-mastering and launch on April 21 of an Asian indie film classic in the psychological thriller genre.

Read

Commented by André Will-Laudien on April 12th, 2022 | 18:27 CEST

Ukraine: K+S, Bayer, Ximen Mining - Fertilizer shares against the food disaster!

  • PreciousMetals
  • Agriculture

Ukraine is one of the leading export nations of wheat worldwide. However, the so-called "granary of Europe" does not primarily supply European countries because the main customers are mainly in Asia and North Africa. The most important destination for Ukrainian wheat in 2020, for example, was Egypt. The largest amount is transported overland to Odessa, where it is shipped. But now Putin has started bombing the important port city. Diesel and fertilizer are becoming scarce, so it is all the more important that there are Western specialists who are trying to secure a supply of food through special deliveries in fertilizer and technology. Where are the opportunities for investors?

Read

Commented by André Will-Laudien on April 4th, 2022 | 12:19 CEST

Bayer, Cardiol Therapeutics, Formycon, NanoRepro: Top Biotech Stocks - Delivering!

  • Biotechnology

Due to various public easing measures, the Corona pandemic is increasingly fading into the background. It has long been a hot ride for the stock market, especially for vaccine producers, but now investors are shifting their focus to other stocks in the biotech segment. After all, there are still many diseases that confront humanity with unresolved mysteries, and the field of human medical research seems endless. We focus on interesting stocks from the sector, which corrected strongly in the wake of the Ukraine downturn but are now trending north again. These trends are still in their infancy.

Read

Commented by Fabian Lorenz on March 24th, 2022 | 10:58 CET

Nel and Bayer shares in demand - when will Barsele Minerals explode?

  • Gold
  • Hydrogen

The stock and commodity markets remain volatile. Prices are driven by the war in Ukraine and the Corona pandemic. In recent days, commodities have been on the rise again. Brent oil is trading at around USD 120 per barrel, and gold is again setting its sights on the USD 2,000 mark. But even in this difficult-to-navigate environment, equities can make gains. Bayer shares, for example, have developed positively in recent weeks. And analysts see up to 50% upside potential for the DAX company. The invasion of Russia has also accelerated the move toward renewable energies. Hydrogen plays a central role in this. Nel has been able to profit from the fantasy in recent weeks and has now also announced a new order. Gold explorer Barsele Minerals has catch-up potential. According to a study, the share already had a lot of potential at a gold price of USD 1,350.

Read